The Airports Authority of India (AAI) on March 25 integrated the upper airspace, above 25,000 feet, over the North Eastern Region of India with the Kolkata communications, navigation, surveillance & air traffic management facility, the airports regulator said in a press release.
The move is in line with the airport regulator's plan to harmonize the upper airspace in India with four flight information regions in Chennai, Kolkata, Delhi and Mumbai to establish a single continuum of the upper airspace.
Upper Airspace Harmonization is a process by which aircrafts flying in airspace above a particular height are controlled from a central location with multiple airspace sectors.
The Airports Authority of India's move is expected to enhance the capacity, efficiency and safety in the air space over India, the regulator said.
Upper Airspace Harmonization is also expected to facilitate the provision of seamless air traffic management services resulting in reduction of the cockpit work load.
Frequently Asked Questions
A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.
There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.
Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.